Interphase clinical trials: Phase III/Phase IV

被引:0
|
作者
O'Quigley, J
Xu, RH
Blin, P
Charpak, Y
机构
[1] Univ Calif San Diego, Dept Math, La Jolla, CA 92093 USA
[2] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat, Boston, MA USA
[3] EVAL, Paris, France
关键词
clinical trial; extrapolation; Phase III studies; Phase IV studies; prediction; proportional hazard regression; regression errors; survival analysis;
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In this paper we investigate ways in which the results of a controlled Phase III clinical trial can be used in subsequent Phase IV, and possibly further Phase III studies. Specifically we are interested in; 1) developing particular hypothesis relating to a modified study population, 2) studying how changes in the particularities of the Phase III study group can influence certain outcome variables of interest and 3) using the results of the Phase III study applied to specific target groups, having particular characteristics, to updating observations from the Phase III study with information obtained at a later stage. These issues are all concerned with the way in which we can exploit information from a Phase III trial, information that is of high quality but not necessarily directly related to the way in which many post Phase III studies, focussing on different patient population groups, are carried out. Since it is often these post Phase III studies that have the strongest influence on clinical practice we aim to develop a framework around which the post Phase III studies might be structured.
引用
收藏
页码:773 / 782
页数:10
相关论文
共 50 条
  • [1] Sample size justification in phase III/IV clinical trials
    Richardson, D
    Leurgans, S
    [J]. NEUROEPIDEMIOLOGY, 1998, 17 (02) : 63 - 66
  • [2] NAFLD and nutraceuticals: a review of completed phase III and IV clinical trials
    Hegazi, Omar E. E.
    Alalalmeh, Samer O. O.
    Alnuaimi, Ghala Rashid Humaid
    Shahwan, Moyad
    Jairoun, Ammar Abdulrahman
    Alorfi, Nasser M. M.
    Majrashi, Shaker A. A.
    Alkhanani, Mustfa Faisal
    Alkhattabi, Abdullah
    Alourfi, Mansour M. M.
    Alsolami, Faris A. A.
    Alsharif, Saeed
    Alshahrani, Hatim
    [J]. FRONTIERS IN MEDICINE, 2023, 10
  • [3] A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis
    Waligora-Dziwak, Katarzyna
    Danczak-Pazdrowska, Aleksandra
    Jenerowicz, Dorota
    [J]. JOURNAL OF CLINICAL MEDICINE, 2024, 13 (14)
  • [4] PHASE-IV CLINICAL-TRIALS
    SPRIET, A
    IMBS, JL
    [J]. SEMAINE DES HOPITAUX, 1987, 63 (1-2): : 47 - 48
  • [5] Symptomatic thinking: the current state of Phase III and IV clinical trials for cognition in schizophrenia
    Talpos, John C.
    [J]. DRUG DISCOVERY TODAY, 2017, 22 (07) : 1017 - 1026
  • [6] On the choice of doses for phase III clinical trials
    Lisovskaja, Vera
    Burman, Carl-Fredrik
    [J]. STATISTICS IN MEDICINE, 2013, 32 (10) : 1661 - 1676
  • [7] Phase III and phase IV trials: Noninvasive assessment of efficacy endpoints in vessel walls
    Levenson, J
    Simon, A
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (8A): : 67F - 68F
  • [8] Empowering phase II clinical trials to reduce phase III failures
    De Martini, Daniele
    [J]. PHARMACEUTICAL STATISTICS, 2020, 19 (03) : 178 - 186
  • [9] Guidelines for the critical reading of phase III and IV clinical trials on disease modifying drugs for MS
    Rivero-de-Aguilar, A.
    Perez-Rios, M.
    Mascarenas-Garcia, M.
    Llaneza-Gonzalez, M.
    Mulero, P.
    Ruano-Ravina, A.
    Puente-Hernandez, M.
    Varela-Lema, L.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 250 - 250
  • [10] GUIDELINES FOR PHASE-IV CLINICAL-TRIALS
    TEEHAN, M
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1994, 39 (10): : 629 - 630